Navigation Links
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Date:5/31/2008

from preclinical studies, and suggests that XL765 inhibits PI3K and both mTOR/raptor and mTOR/rictor in patients.

XL765 administration also resulted in the augmentation of food-induced changes in plasma insulin in an exposure-dependent fashion, but generally had no effect on plasma glucose levels. PI3K is known to play a key role in insulin signaling, and PI3K inhibition has been shown to increase insulin levels in preclinical models.

Five patients with various cancers have experienced stable disease for at least three months, including two patients (colon adenocarcinoma and mesothelioma) with stable disease lasting six months or longer.

Administration of XL765 at doses up to 60 mg BID has been generally well-tolerated, with no dose-limiting toxicities reported. At the maximum administered dose of 120 mg BID, dose-limiting toxicities included anorexia, hypophosphatemia, and reversible increases in liver enzyme levels. The preliminary maximum tolerated dose (MTD) is 60 mg BID, and dose ranging is ongoing to establish the MTD for both twice-daily and once-daily dosing regimens.

"The encouraging pharmacodynamic results in this trial are consistent with the target profile of XL765, and clearly demonstrate that XL765 inhibits both PI3K and mTOR in patients at doses that are well-tolerated," said Michael M. Morrissey, PhD, President of Research and Development at Exelixis. "We are very encouraged by these data, and believe they support the development of this compound both as a single agent and in combination with other anti-cancer agents."

"These positive data set the stage for possibly major advances toward the development of treatments for the many different cancers that involve the PI3K pathway," said Dr. Papadopoulos. "For perhaps the first time, we have seen inhibition of the PI3K pathway in humans, with good tolerability. The data suggest that XL765 has potential both alone and in combination with other therapies."

Phase 1b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Delivery of the Report will take 2-3 ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... on Global and Chinese Hemodialysis Machine industry. The ... Machine including its classification, application and manufacturing technology. ... manufacturers of Hemodialysis Machine listing their product specification, ...
(Date:7/24/2014)... 24, 2014 Cancer patients in the west of ... cancer treatment closer to home when a new radiotherapy center ... Medical Systems (NYSE: VAR ) has been selected ... in June for four TrueBeam™ medical linear accelerators. ... and efficient radiotherapy and radiosurgery treatments, will replace older treatment ...
(Date:7/24/2014)... July 24, 2014  Blueprint Medicines (Blueprint), a leader ... cancer patients, today announced the appointment of Jeffrey ... joins Blueprint from Algeta ASA, where he served on ... the acquisition by Bayer. Mr. Albers succeeds Alexis ... Partner at Third Rock Ventures, who will remain an ...
Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the diagnosis and treatment of coronary and ... operating results for the third quarter of fiscal 2011 on ... conference call to discuss its financial results and operating activities ...
... Oct. 17, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. ... the "Company"), a developer, manufacturer and distributor of botanical ... today announced the results of its annual general meeting ... 2011 in Harbin, China. At the Annual ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2China Botanic Announces Results of Annual General Meeting 2
(Date:7/24/2014)... As the age of marriage and ... as a way to ensure future family building options ... advancing reproductive age. Vitrification technology, a fast freeze method ... technology that allows a woman to have multiple eggs ... which are then stored for future use. When circumstances ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
(Date:7/24/2014)... 2014 In a recent report by CBS ... put an end to criminal penalties associated with possession of ... for marijuana reform in Washington DC, giving it one of ... replaces criminal penalties for possession of one ounce of marijuana ... possession of more than an ounce of marijuana remain criminal ...
(Date:7/24/2014)... from Penn Medicine shows that incisionless transcatheter aortic ... stay by 30 percent and has no impact ... conventional transfemoral TAVR, which requires an incision in ... the current issue of Circulation: Cardiovascular Interventions ... aortic valve without a traditional open-heart surgical approach. ...
(Date:7/24/2014)... PROVIDENCE, R.I. Lynn E. Taylor, M.D., director ... states in the July, 2014 Rhode Island ... C" that eliminating hepatitis c virus infection (hep ... benefits, enhance capacity to address other health challenges, ... HCV in the United States, Taylor says, include ...
Breaking Medicine News(10 mins):Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 2Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 3Health News:Expanded Financial Options for Women Interested in Proactive Egg Freezing at Shady Grove Fertility 4Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Washington D.C. Decriminalizes Marijuana 2Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... , FRIDAY, March 25 (HealthDay News) -- A small army ... of sick and dying animals from a rural North Carolina ... More than 400 animals -- 17 species in all, ... had been living in squalor with a middle-aged couple claiming ...
... FRIDAY, March 25 (HealthDay News) -- People looking for a ... joints sometimes turn to biking. Rather than a 30-minute jog ... hours on the bike, with little or no joint strain. ... physical activity raise a new problem: How to keep the ...
... Aurora, Colo. (March 24, 2011)A research team at the University ... be used to diagnose colon cancer earlier. It is possible ... the cancer. Colon cancer is the third most common cancer ... it, according to the American Cancer Society. This enzyme biomarker ...
... The US Food and Drug Administration announced today that ... the treatment of patients with metastatic melanoma. It is the ... with advanced melanoma. Ipilimumab uses a novel approach known ... attack cancer. The therapy, originally known as anti-CTLA-4, was developed ...
... Research Chair Peter Shizgal who investigates the roots ... recognized by his peers with the prestigious Prix Adrien ... Psychology and a member of the Centre for Studies ... qubcoise pour la recherche en psychologie (Quebec Society for ...
... , FRIDAY, March 25 (HealthDay News) -- A poor diet ... postmenopausal women, a new study has found. Researchers analyzed ... found that deficiencies in more than a single nutrient were ... Risk increased 44 percent with deficiencies in three nutrients. ...
Cached Medicine News:Health News:Animal 'Hoarding' Often Tied to Mental Illness 2Health News:Animal 'Hoarding' Often Tied to Mental Illness 3Health News:Animal 'Hoarding' Often Tied to Mental Illness 4Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 2Health News:Cyclists Urged to Prep Their Bodies for the Long Haul 3Health News:University of Colorado team identifies new colon cancer marker 2Health News:Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma 2Health News:Peter Shizgal distinguished by his peers 2Health News:Poor Eating Habits May Lead to Anemia in Older Women 2
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
... the NeuFlex™ MCP and/or PIP ... on numerous research studies of ... the MCP/PIP joint. This prosthesis ... the phalanx, by settling the ...
... Blackstone Anterior Cervical Plate System ... implantation. The innovative design of ... prevents screw back-out. The implant ... Simple, reliable instrumentationincluding innovations like ...
... closely match the natural anatomy of ... Titanium construction incorporates an 8-degree cranial ... design prevents screws from backing out. ... for X-ray control of the procedure. ...
Medicine Products: